Cause of death
|
Simvastatin-allocated (10,269)
|
Placebo- allocated (10,267)
|
Death rate ratio (& 95% CI)
|
P-value
|
---|
Coronary
| | | | |
---|
Acute MI
|
141 (1.4%)
|
191 (1.9%)
|
0.73 (0.59 – 0.91)
| |
Sudden death
|
147 (1.4%)
|
154 (1.5%)
|
0.95 (0.75 – 1.19)
| |
Heart failure*
|
65 (0.6%)
|
78 (0.8%)
|
0.82 (0.59 – 1.15)
| |
Other coronary
|
234 (2.3%)
|
284 (2.8%)
|
0.82 (0.69 – 0.97)
| |
Subtotal: Coronary
|
587 (5.7%)
|
707 (6.9%)
|
0.82 (0.74 – 0.92)
|
0.0005
|
Stroke
| | | | |
Haemorrhagic
|
23 (0.2%)
|
24 (0.2%)
|
0.95 (0.54 – 1.68)
| |
Ischaemic (or unknown)
|
73 (0.7%)
|
95 (0.9%)
|
0.76 (0.56 – 1.03)
| |
Subtotal: Stroke
|
96 (0.9%)
|
119 (1.2%)
|
0.80 (0.61 – 1.05)
|
0.1
|
Other vascular
| | | | |
Peripheral vascular
|
58 (0.6%)
|
63 (0.6%)
|
0.91 (0.64 – 1.30)
| |
Other cardiac*
|
40 (0.4%)
|
48 (0.5%)
|
0.83 (0.54 – 1.25)
| |
Subtotal: Other vascular
|
98 (1.0%)
|
111 (1.1%)
|
0.88 (0.67 – 1.15)
|
0.3
|
VASCULAR
|
781 (7.6%)
|
937 (9.1%)
|
0.83 (0.75 – 0.91)
|
<0.0001
|
Neoplastic
| | | | |
Respiratory
|
127 (1.2%)
|
133 (1.3%)
|
0.94 (0.74 – 1.20)
| |
Gastrointestinal
|
112 (1.1%)
|
103 (1.0%)
|
1.08 (0.82 – 1.41)
| |
Genitourinary
|
47 (0.5%)
|
46 (0.4%)
|
1.01 (0.67 – 1.52)
| |
All others
|
73 (0.7%)
|
62 (0.6%)
|
1.17 (0.83 – 1.63)
| |
Subtotal: Neoplastic
|
359 (3.5%)
|
345 (3.4%)
|
1.03 (0.89 – 1.19)
|
0.7
|
Other non-vascular
| | | | |
Respiratory
|
90 (0.9%)
|
114 (1.1%)
|
0.78 (0.59 – 1.03)
| |
Gastrointestinal
|
35 (0.3%)
|
41 (0.4%)
|
0.85 (0.54 – 1.33)
| |
Other medical†
|
47 (0.5%)
|
49 (0.5%)
|
0.95 (0.64 – 1.42)
| |
Non-medical
|
16 (0.2%)
|
21 (0.2%)
|
0.75 (0.40 – 1.44)
| |
NON-VASCULAR
|
547 (5.3%)
|
570 (5.6%)
|
0.95 (0.85 – 1.07)
|
0.4
|
ALL DEATHS
|
1328 (12.9%)
|
1507 (14.7%)
|
0.87 (0.81 – 0.94)
|
0.0003
|
- * Heart failure deaths were subdivided into those considered to be due to coronary disease and those (5 versus 8) due to other vascular (or unknown) causes.
- † Includes renal, infectious, metabolic, neurological and unknown deaths.